H.C. Wainwright Sticks to Their Buy Rating for Aravive (ARAV)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Aravive (ARAVResearch Report) today and set a price target of $7.00. The company’s shares opened today at $1.40.

According to TipRanks, Pantginis is an analyst with an average return of -19.7% and a 26.95% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Decibel Therapeutics, and Biomea Fusion.

Aravive has an analyst consensus of Strong Buy, with a price target consensus of $9.67, which is a 590.71% upside from current levels. In a report released on October 27, Roth Capital also maintained a Buy rating on the stock with a $10.00 price target.

See the top stocks recommended by analysts >>

Based on Aravive’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $1.62 million and a GAAP net loss of $18.48 million. In comparison, last year the company earned a revenue of $3.79 million and had a GAAP net loss of $7.11 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aravive, Inc. is a clinical-stage biotechnology company, which engages in developing new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments, and immune suppression. The company was founded on December 10, 2008 and is headquartered in Houston, TX.

Read More on ARAV:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More